Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by River Global Investors LLP

River Global Investors LLP boosted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 13.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,479 shares of the medical equipment provider’s stock after buying an additional 2,012 shares during the period. River Global Investors LLP’s holdings in Zimmer Biomet were worth $2,006,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. PFG Advisors boosted its stake in Zimmer Biomet by 4.6% during the 4th quarter. PFG Advisors now owns 1,899 shares of the medical equipment provider’s stock valued at $231,000 after purchasing an additional 84 shares during the period. Quent Capital LLC raised its position in shares of Zimmer Biomet by 21.6% during the 4th quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock worth $63,000 after buying an additional 92 shares in the last quarter. Pinnacle Associates Ltd. raised its position in shares of Zimmer Biomet by 5.0% during the 3rd quarter. Pinnacle Associates Ltd. now owns 2,020 shares of the medical equipment provider’s stock worth $227,000 after buying an additional 97 shares in the last quarter. Financial Advocates Investment Management raised its position in shares of Zimmer Biomet by 3.8% during the 3rd quarter. Financial Advocates Investment Management now owns 2,625 shares of the medical equipment provider’s stock worth $295,000 after buying an additional 97 shares in the last quarter. Finally, Stokes Family Office LLC raised its position in shares of Zimmer Biomet by 4.1% during the 3rd quarter. Stokes Family Office LLC now owns 2,498 shares of the medical equipment provider’s stock worth $280,000 after buying an additional 99 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Insider Transactions at Zimmer Biomet

In other news, VP Chad F. Phipps sold 26,156 shares of the stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the transaction, the vice president now owns 44,145 shares in the company, valued at approximately $5,677,929.90. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.95% of the stock is currently owned by company insiders.

Analyst Ratings Changes

ZBH has been the topic of a number of recent analyst reports. Canaccord Genuity Group restated a “hold” rating and set a $130.00 price target on shares of Zimmer Biomet in a research report on Friday, February 23rd. Oppenheimer boosted their target price on shares of Zimmer Biomet from $150.00 to $155.00 and gave the stock an “outperform” rating in a report on Friday. Citigroup boosted their target price on shares of Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. Royal Bank of Canada reiterated an “outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a report on Friday, February 9th. Finally, Truist Financial dropped their target price on shares of Zimmer Biomet from $137.00 to $130.00 and set a “hold” rating on the stock in a report on Friday. One analyst has rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and an average price target of $135.40.

Zimmer Biomet Stock Up 2.7 %

Zimmer Biomet stock traded up $3.20 during trading hours on Friday, hitting $121.66. The company had a trading volume of 1,847,585 shares, compared to its average volume of 1,304,580. The firm has a market capitalization of $25.00 billion, a P/E ratio of 26.33, a price-to-earnings-growth ratio of 2.23 and a beta of 1.03. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.66 and a quick ratio of 0.78. The firm’s fifty day moving average is $125.30 and its 200-day moving average is $120.21. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $102.00 and a fifty-two week high of $147.50.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.87 by $0.07. The firm had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.89 EPS. On average, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th were paid a dividend of $0.24 per share. The ex-dividend date was Wednesday, March 27th. This represents a $0.96 annualized dividend and a dividend yield of 0.79%. Zimmer Biomet’s dividend payout ratio (DPR) is 20.78%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.